ライフサイエンスコーパス: hydroxycholesterol

1 cid biosynthesis intermediates (27- and 7,27-hydroxycholesterol).

2 lipoprotein and sterols (cholesterol and 25-hydroxycholesterol).

3 terol 25-hydroxylase and the synthesis of 25-hydroxycholesterol.

4 f NPC1 and complexes with cholesterol and 25-hydroxycholesterol.

5 domain that can bind both cholesterol and 25-hydroxycholesterol.

6 of a closely eluting isomeric oxysterol, 25-hydroxycholesterol.

7 ostasis, we synthesized the enantiomer of 25-hydroxycholesterol.

8 required the conversion of cholesterol to 27-hydroxycholesterol.

9 nd to form two new products, one being 7beta-hydroxycholesterol.

10 election in high levels of the oxysterol, 25-hydroxycholesterol.

11 ergosterol, cholesterol, and 7-, 20- and 25-hydroxycholesterol.

12 ion of APP may be to produce low levels of 7-hydroxycholesterol.

13 approximately 1000-fold more potent than 27-hydroxycholesterol.

14 te block of the induction of apoptosis by 25-hydroxycholesterol.

15 gh-fat diet via its oxysterol metabolite, 27-hydroxycholesterol.

16 talyzes the synthesis of the oxysterol 24(S)-hydroxycholesterol.

17 ion, than the widely used LXR agonist 22-(R)-hydroxycholesterol.

18 s, including 22(R)-hydroxycholesterol and 24-hydroxycholesterol.

19 ed for by the formation and excretion of 24S-hydroxycholesterol.

20 e very little affinity for cholesterol or 25-hydroxycholesterol.

21 -fold by 9CRA, and 37-fold by 9CRA and 22(R)-hydroxycholesterol.

22 sion of ABC8 following incubation with 22(R)-hydroxycholesterol.

23 no enhanced calcium uptake in response to 25-hydroxycholesterol.

24 droxycholesterol, and to a lesser extent, 25-hydroxycholesterol.

25 rs the protein resistant to inhibition by 25-hydroxycholesterol.

26 hen cells were grown in medium containing 25-hydroxycholesterol.

27 on with either low density lipoprotein or 25-hydroxycholesterol.

28 tivities of a typical, regulatory sterol: 25-hydroxycholesterol.

29 dium renders them resistant to killing by 25-hydroxycholesterol.

30 nd selection for resistance to killing by 25-hydroxycholesterol.

31 l synthesizing enzymes in the presence of 25-hydroxycholesterol.

32 the protein's ability to be inhibited by 25-hydroxycholesterol.

33 and renders it resistant to inhibition by 25-hydroxycholesterol.

34 on tumour development were independent of 27-hydroxycholesterol.

35 ant cells, partly via the biosynthesis of 27-hydroxycholesterol.

36 of the estrogenic cholesterol metabolite 27-hydroxycholesterol.

37 the brain, the predominant oxysterol was 24S-hydroxycholesterol.

38 oxycholesterol, 27-hydroxycholesterol, 22(R)-hydroxycholesterol, 20(S)-hydroxycholesterol, and 24(S),

39 22(R)-hydroxycholesterol (22(R)-OHC), 25-OHC, and 27-OHC each

40 c hydroxylations with formation first of 22R-hydroxycholesterol (22-HC) and then 20alpha,22R-dihydrox

41 We observed that the oxysterol 22-hydroxycholesterol (22-HC) in combination with its oblig

42 erivatives such as 25-hydroxycholesterol, 27-hydroxycholesterol, 22(R)-hydroxycholesterol, 20(S)-hydr

43 Other proposed LXR ligands, including 20(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, and 24(S),

44 at involve the progressive production of 22R-hydroxycholesterol (22HC) and 20alpha,22R-dihydroxychole

45 r brain-derived cholesterol metabolite 24(S)-hydroxycholesterol (24(S)-HC) is a very potent, direct,

46 In the central nervous system, 24(S)-hydroxycholesterol (24(S)-HC) is an oxysterol synthesize

47 Serum and CSF 24(S)-hydroxycholesterol (24[S]-HC), which serves as a biomark

48 urally occurring oxysterols, including 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, and 24(S),

49 me Cyp46a1, which generates the oxysterol 24-hydroxycholesterol (24S-HC) in a pancreatic neuroendocri

50 tion of the brain cholesterol metabolite 24S-hydroxycholesterol (24S-OHC) found in B6.Mecp2-null mice

51 The levels of 24(S)-hydroxycholesterol (24S-OHC) were significantly reduced

52 ing enzyme for cholesterol conversion to 24S-hydroxycholesterol (24S-OHC).

53 age, A1- causes a 32% content increase in 24-hydroxycholesterol (24SOH), the major oxysterol in the b

54 Concentrations of circulating 24S-hydroxycholesterol (24SOHChol) are of interest as a prac

55 search for a membrane protein that binds 25-hydroxycholesterol (25-HC) and other oxysterols.

56 Here, we demonstrate that production of 25-hydroxycholesterol (25-HC) by macrophages is required to

57 that are unable to produce the oxysterol 25-hydroxycholesterol (25-HC) overproduce inflammatory inte

58 We further showed that production of 25-hydroxycholesterol (25-HC) promotes macrophage foam cell

59 shown that side-chain oxysterols, such as 25-hydroxycholesterol (25-HC), alter membrane structure in

60 that in vitro additions of the oxysterol 25-hydroxycholesterol (25-HC), exogenous cytosol, and ATP t

61 lesterol and its hydroxylated derivative, 25-hydroxycholesterol (25-HC), inhibit cholesterol synthesi

62 SREBP activation was also blocked by 25-hydroxycholesterol (25-HC).

63 (3)H]cholesterol (K(d), 130 nM) and [(3)H]25-hydroxycholesterol (25-HC, K(d), 10 nM) with one sterol

64 7beta-hydroxycholesterol (7beta-OH), and 25-hydroxycholesterol (25-OH).

65 The oxysterol 25-hydroxycholesterol (25HC) plays multiple roles in lipid

66 infection and that its enzymatic product, 25-hydroxycholesterol (25HC), was a critical mediator of ho

67 iviral activity through the production of 25-hydroxycholesterol (25HC), which is believed to inhibit

68 veloped viruses through the production of 25-hydroxycholesterol (25HC).

69 holesterol to a soluble antiviral factor, 25-hydroxycholesterol (25HC).

70 25-Hydroxycholesterol (25OH) competitively inhibits this ex

71 ls, 22(R)-hydroxy-cholesterol (22ROH) and 25-hydroxycholesterol (25OH), and a nonsterol activator of

72 25-Hydroxycholesterol (25OHC) is an enzymatically derived o

73 pc1-/- mice showed decreased synthesis of 27-hydroxycholesterol (27-HC), an endogenous LXR ligand; de

74 Here, we show that excess 27-hydroxycholesterol (27-OH), a cholesterol metabolite pas

75 ow that the cholesterol oxidation product 27-hydroxycholesterol (27-OHC) increases BACE1 and Abeta le

76 XRs include oxysterol derivatives such as 25-hydroxycholesterol, 27-hydroxycholesterol, 22(R)-hydroxy

77 tment with the alternative ERalpha ligand 27-hydroxycholesterol (27HC) induced ERalpha-dependent HSC

78 east cancer metastasis via its metabolite 27-hydroxycholesterol (27HC) that acts on immune myeloid ce

79 27-Hydroxycholesterol (27HC), a derivative of cholesterol f

80 Here, we show that 27-hydroxycholesterol (27HC), a primary metabolite of chole

81 Here we show that 27-hydroxycholesterol (27HC), an abundant cholesterol metab

82 t treatment of prostate cancer cells with 27-hydroxycholesterol (27HC), an enzymatic product of CYP27

83 studies have indicated that the oxysterol 27-hydroxycholesterol (27HC), and not cholesterol per se, m

84 The oxysterol 27-hydroxycholesterol (27HC), synthesized by the mitochondr

85 e endogenous estrogen receptor antagonist 27-hydroxycholesterol (27OHC) is correlated with LDLC level

86 ntracellular domain (AICD) in response to 27-hydroxycholesterol (27OHC), an oxidized cholesterol meta

87 to 1, whereas the unnatural oxysterol 22(S)-hydroxycholesterol (4) was shown to be an antagonist of

88 ubstrates, whereas 7-ketocholesterol, 7 beta-hydroxycholesterol, 5 beta,6 beta-epoxycholesterol, and

89 inance of the 7-oxygenated products, 7 alpha-hydroxycholesterol (7 alpha HCh), 7 beta-hydroxycholeste

90 pha-hydroxycholesterol (7 alpha HCh), 7 beta-hydroxycholesterol (7 beta HCh), and 7-ketocholesterol (

91 velop cholestasis before up-regulation of 27-hydroxycholesterol 7alpha-hydroxylase activity.

92 One of the 7-oxygenated sterols, 7alpha-hydroxycholesterol (7alpha-OHC), serves as a key interme

93 varying concentrations of cholesterol, 7beta-hydroxycholesterol (7beta-OH), and 25-hydroxycholesterol

94 pstream promoter was induced 7-fold by 22(R)-hydroxycholesterol, 8-fold by 9CRA, and 37-fold by 9CRA

95 p to 2.5-fold) by LXR activation using 24(S)-hydroxycholesterol (a cerebral cholesterol metabolite) o

96 A>G (P<0.01) and c.521T>C (P<0.05) and 4beta-hydroxycholesterol, a CYP3A activity marker (adjusted R(

97 while providing a complementary source of 25-hydroxycholesterol, a modulator of immune cell function

98 oxysterols, we assessed the effect of 22-(R)-hydroxycholesterol, a natural ligand of the liver X rece

99 25-hydroxycholesterol, a potent regulator of SCAP in vivo,

100 nd APP can oxidize cholesterol to form 7beta-hydroxycholesterol, a proapoptotic oxysterol that was ne

101 uction of cholesterol 25-hydroperoxide to 25-hydroxycholesterol, a role of potential significance for

102 ffects on serum levels of the oxysterol, 24S-hydroxycholesterol, a substrate of the encoded enzyme.

103 iquid chromatography analysis showed that 27-hydroxycholesterol accumulated in the mitochondria of St

104 27-Hydroxycholesterol, an abundant oxysterol synthesized by

105 nzyme in humans converting cholesterol to 27-hydroxycholesterol, an oxysterol of multiple functions,

106 ia conversion of excess cholesterol into 24S-hydroxycholesterol, an oxysterol that is readily secrete

107 acid and several oxysterols, including 22(R)-hydroxycholesterol and 24-hydroxycholesterol.

108 ibroblasts fail to appropriately generate 25-hydroxycholesterol and 27-hydroxycholesterol in response

109 rations, the efficiencies of oxidation of 27-hydroxycholesterol and 3beta-hydroxy-5-cholestenal to th

110 ophage-like cell line P388D1, oxysterols (25-hydroxycholesterol and 7-ketocholesterol) induced the de

111 Oxysterols (25-hydroxycholesterol and 7-ketocholesterol) reversed the i

112 by incubating cells with the oxysterols, 25-hydroxycholesterol and 7-ketocholesterol; these findings

113 was induced in an additive fashion by 22(R)-hydroxycholesterol and 9-cis-retinoic acid (9CRA), sugge

114 sh variant of amyloid precursor protein, 22R-hydroxycholesterol and 9-cis-retinoic acid induced ABCA1

115 without a double bond between C5-C6 (7alpha-hydroxycholesterol and cholestanol, respectively) and in

116 In addition, we show that formation of 27-hydroxycholesterol and cholestenoic acid, products of CY

117 es OSBP Golgi localization in response to 25-hydroxycholesterol and cholesterol depletion, impairs CE

118 s, we demonstrated that preincubations in 25-hydroxycholesterol and cholesterol lead to increased apo

119 ckstrin homology (PH) domain (ORP4S) bind 25-hydroxycholesterol and extract and transfer cholesterol

120 Here, we report that the oxysterol 25-hydroxycholesterol and geranylgeraniol combine to trigge

121 on of reductase were tightly regulated by 25-hydroxycholesterol and geranylgeraniol.

122 nued to process SREBPs in the presence of 25-hydroxycholesterol and hence they resisted killing by th

123 hrome P450 enzyme that has preference for 24-hydroxycholesterol and is expressed in the liver.

124 uclear hormone receptor LXR, including 22(R)-hydroxycholesterol and T0901317.

125 lpha-hydroxylase is to metabolize 25- and 27-hydroxycholesterol and that loss of this enzyme in the l

126 rystal structures of rat ATX bound to 7alpha-hydroxycholesterol and the bile salt tauroursodeoxychola

127 e two steroid substrates cholesterol and 24S-hydroxycholesterol and the protein redox partner adrenod

128 s, including 20(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, and 24(S),25-epoxycholesterol, could

129 s, including 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, and 24(S),25-epoxycholesterol.

130 cholesterol, 22(R)-hydroxycholesterol, 20(S)-hydroxycholesterol, and 24(S),25-epoxycholesterol.

131 sterols that included 25-, 20(S)-, and 22(R)-hydroxycholesterol, and by a retinoid X receptor-specifi

132 eceptor pores by pregnenolone sulfate, 24(S)-hydroxycholesterol, and docosahexaenoic acid, three endo

133 roduces biologically active oxysterol, 24(S)-hydroxycholesterol, and is also the first step in enzyma

134 topically applying the LXR activator, 22(R)-hydroxycholesterol, and non-oxysterol activators of LXR,

135 l, lanosterol, ketosterone, 5-cholestene, 25-hydroxycholesterol, and testosterone), we can discuss ho

136 ation and inhibition of SREBP cleavage by 25-hydroxycholesterol, and they indicate that these two pro

137 activity that converts cholesterol into 24S-hydroxycholesterol, and to a lesser extent, 25-hydroxych

138 , such as cis-unsaturated fatty acids, 24(S)-hydroxycholesterol, and various neurosteroids.

139 f new cholesterol and the secretion of 24(S)-hydroxycholesterol are closely coupled and that at least

140 5 alpha,6 alpha-epoxycholesterol and 7 alpha-hydroxycholesterol are comparable with cholesterol as th

141 wever, levels of another major oxysterol, 24-hydroxycholesterol, are not increased in these mice, sug

142 aved SREBP-1, consistent with the role of 24-hydroxycholesterol as an LXR agonist.

143 defined spectral changes while generating 25-hydroxycholesterol as the major product.

144 or 7-ketocholesterol to 101+/-12% for 7alpha-hydroxycholesterol at 200ngg(-1) and from 82+/-2% for 7-

145 ated by 24(S), 25-epoxycholesterol and 24(S)-hydroxycholesterol at physiologic concentrations.

146 25-Hydroxycholesterol, at concentrations higher than 1 micr

147 rol cholesterol binding without affecting 25-hydroxycholesterol binding.

148 E) had increased in vitro cholesterol and 25-hydroxycholesterol-binding capacity, and cholesterol ext

149 responsible for the rate-limiting step in 27-hydroxycholesterol biosynthesis, significantly reduces m

150 ng cells, sterols such as cholesterol and 25-hydroxycholesterol block the lateral movement of sterol

151 n even in the presence of cholesterol and 25-hydroxycholesterol both of which are known suppressors o

152 -164, and 351-361) and eight peptides in 24S-hydroxycholesterol-bound enzyme (50-64, 65-80, 109-116,

153 ina and RPE, the authors could not detect 27-hydroxycholesterol but unexpectedly found that its oxida

154 The rate of production of 7beta-hydroxycholesterol by APP was approximately 200 times lo

155 ) with subsequent 7alpha-hydroxylation of 27-hydroxycholesterol by oxysterol 7alpha-hydroxylase (CYP7

156 This is important because 25-hydroxycholesterol can be present in significant amounts

157 The conversion of cholesterol to 7alpha-hydroxycholesterol catalyzed by cytochrome P450 7A1 (CYP

158 ty by less than 2-fold and addition of 22(R)-hydroxycholesterol caused a small but significant stimul

159 oblastoma cells with retinoic acid and 22(R)-hydroxycholesterol caused significant increases in secre

160 tiviral role for macrophage production of 25-hydroxycholesterol (cholest-5-en-3beta,25-diol, 25HC) as

161 Second, 24-, 25-, and 27-hydroxycholesterol concentrations were moderately increa

162 By converting cholesterol to 24S-hydroxycholesterol, cytochrome P450 46A1 (CYP46A1) initi

163 In contrast, 24S-hydroxycholesterol decreased levels of LXR-independent S

164 In neuroblastoma cells, 24S-hydroxycholesterol decreased mRNA levels of the choleste

165 22(R)-Hydroxycholesterol decreased NO (*NO) and increased supe

166 sterol 7alpha-hydroxylase, which degrades 25-hydroxycholesterol, decreased serum IgA.

167 d an NADP+-dependent liver microsomal 7alpha-hydroxycholesterol dehydrogenase (7alpha-HCD) activity t

168 nhibitor of 11beta-HSD, was 75 nM for 7alpha-hydroxycholesterol dehydrogenation and 210 nM for cortic

169 The regulation of LC by U18666A or 25-hydroxycholesterol did not affect total cellular sphingo

170 pathway, such as mevalonate, squalene, or 25-hydroxycholesterol, did not alter barrier development.

171 romoter" sterols cholesterol, ergosterol, 25-hydroxycholesterol, epicholesterol, or dihydrocholestero

172 The IC(50) of 24(S)-hydroxycholesterol for inhibiting Abeta secretion was ap

173 rvastatin, but not placebo, reduced serum 27-hydroxycholesterol from 853 ng/ml [interquartile range (

174 urons of the brain and that secretion of 24S-hydroxycholesterol from this tissue in the mouse is deve

175 nd 4) in a coactivator association assay, 27-hydroxycholesterol functionally activated LXR.

176 cells and polymorphonuclear-neutrophils, 27-hydroxycholesterol functions as a biochemical mediator o

177 n P450c27 is also able to further oxidize 27-hydroxycholesterol giving first an aldehyde and then 3be

178 that P450 46A1 can further metabolize 24(S)-hydroxycholesterol, giving 24,25- and 24,27-dihydroxycho

179 25-Hydroxycholesterol had virtually no effect in cells expr

180 of cells with an alkynyl derivative of 20(S)-hydroxycholesterol has allowed us to directly visualize

181 lso similar to the in vitro results with 24S-hydroxycholesterol, HMG CoA reductase and squalene synth

182 vated plasma and tissue levels of 25- and 27-hydroxycholesterol; however, levels of another major oxy

183 eptors seem to mediate adverse effects of 27-hydroxycholesterol in breast cancer when the levels of t

184 ytes incubated in the presence of 25- or 22R-hydroxycholesterol in low calcium.

185 Here we describe a central role for 25-hydroxycholesterol in regulating the immune system.

186 iately generate 25-hydroxycholesterol and 27-hydroxycholesterol in response to LDL cholesterol.

187 The concentrations of 24S-hydroxycholesterol in serum are low in newborn mice, rea

188 450 7A1 oxidation product (dansylated 7alpha-hydroxycholesterol) in human liver extracts using an LC-

189 model to identify its known product, 7alpha-hydroxycholesterol, in liver extracts.

190 Sterols such as 25-hydroxycholesterol inactivate SCAP, suppressing SREBP pr

191 LC extraction by 25-hydroxycholesterol increased APAP-mediated mitophagy and

192 24S-hydroxycholesterol increased levels of SREBP-1 mRNA and

193 22R-hydroxycholesterol increased transglutaminase 1 and invo

194 the hydrosoluble cholesterol derivative, 22R-hydroxycholesterol, increased steroid production by the

195 ciency of hydroxylation of cholesterol to 27-hydroxycholesterol indicating that the first hydroxylati

196 o restore inhibition of SREBP cleavage by 25-hydroxycholesterol, indicating that the ACAT deficiency

197 c acid, or eicosapentaenoic acid, but not 25-hydroxycholesterol, induced ACAT1 mRNA levels 1.5--2-fol

198 cium channel blocker nifedipine prevented 25-hydroxycholesterol induction of apoptosis.

199 7beta-Hydroxycholesterol inhibited secretion of soluble APP fr

200 potent suppressor of SREBP-2 activation, 25-hydroxycholesterol, inhibits CYP4F2 mRNA induction by lo

201 25-Hydroxycholesterol is a natural ligand of LXRs that is p

202 ate that in a reconstituted system, after 27-hydroxycholesterol is formed from cholesterol, it is rel

203 by promoters bearing SRE-1 element(s) by 25-hydroxycholesterol is increased by C18 fatty acid supple

204 ummary, neither SREBP-regulated genes nor 27-hydroxycholesterol is involved in setting the ER cholest

205 25-Hydroxycholesterol is produced in mammalian tissues.

206 Oxygenated sterols such as 25-hydroxycholesterol kill Chinese hamster ovary cells beca

207 Here, we show that 25-, 26-, or 27-hydroxycholesterol, known suppressors of cholesterol bio

208 sterol, and desmosterol), and six do not (25-hydroxycholesterol, lanosterol, androstenolone, coprosta

209 /day for 9 weeks in 14 SPG5 patients with 27-hydroxycholesterol levels in serum as the primary outcom

210 Moreover, 27-hydroxycholesterol levels in serum correlated with disea

211 rvastatin treatment can effectively lower 27-hydroxycholesterol levels in serum of SPG5 patients.

212 Similarly, 25-hydroxycholesterol levels in serum were reduced.

213 Mouse 27-hydroxycholesterol levels in the plasma, brain, and live

214 Mouse plasma and hepatic 27-hydroxycholesterol levels were decreased 2.6- and 1.6-fo

215 These effects of 22R-hydroxycholesterol may provide a novel strategy to decre

216 f mature SREBP1, known to be decreased by 25-hydroxycholesterol, mediates the changes in the lipoprot

217 l (CHOL), 7-ketocholesterol (KETO), or 7beta-hydroxycholesterol (OHCHOL).

218 the differing effects of cholesterol and 25-hydroxycholesterol on bilayer properties.

219 of exogenous low density lipoprotein and 25-hydroxycholesterol on HMG-CoA reductase activity from sk

220 The robust effects of 27-hydroxycholesterol on metastasis requires myeloid immune

221 ds also increase the inhibitory effect of 25-hydroxycholesterol on proteolytic maturation and nuclear

222 tion can enhance the inhibitory effect of 25-hydroxycholesterol on sterol and fatty acid biosynthesis

223 AD, we compared the effects of 24(S)- and 27-hydroxycholesterol on the processing of APP and analyzed

224 fects of the enzymatic product of Cyp46, 24S-hydroxycholesterol, on the cholesterol regulatory genes,

225 treatment of normal hairless mice with 22(R)-hydroxycholesterol or 24(S),25-epoxycholesterol resulted

226 genes associated with the formation of 24(S)-hydroxycholesterol or neurosteroids such as CYP46A1, 3al

227 e to the ER after treatment of cells with 25-hydroxycholesterol or sphingomyelinase.

228 Treatment of cells with 25-hydroxycholesterol or statins, which respectively inhibi

229 Conversely, activation of LXRs by either 25-hydroxycholesterol or synthetic TO901317 stimulates myel

230 ells or human placental explants with 22-(R)-hydroxycholesterol or T0901317 resulted in a clear incre

231 rol preferentially activating SF-1 and 22(R)-hydroxycholesterol preferentially activating LXR.

232 der potency for these two receptors, with 25-hydroxycholesterol preferentially activating SF-1 and 22

233 , dihydrocholesterol, epicholesterol, and 25-hydroxycholesterol) promote formation of DPPC-enriched d

234 On the other hand, 27-hydroxycholesterol, rather than cholesterol itself or bi

235 The pro-metastatic actions of 27-hydroxycholesterol requires both polymorphonuclear-neutr

236 These effects were not seen in a 25-hydroxycholesterol-resistant CHO/CD36 mutant (OX(R)), wh

237 CH25H and its product, 25-hydroxycholesterol, restrict replication of diverse viru

238 tive SREBP cleavage-activating protein or 25-hydroxycholesterol significantly suppressed the effect o

239 25-Hydroxycholesterol stimulated calcium uptake by CHO-K1 c

240 the basal, angiotensin-II-stimulated, and 25-hydroxycholesterol-stimulated syntheses of these steroid

241 of apoB100 were concomitantly reversed by 25-hydroxycholesterol, suggesting that the content of matur

242 bition of APP processing in neurons by 24(S)-hydroxycholesterol suggests that CYP46A1 affects the pat

243 t the hCG-induced cAMP synthesis and the 22R-hydroxycholesterol-supported steroidogenesis.

244 B cells with nanomolar concentrations of 25-hydroxycholesterol suppressed IL-2-mediated stimulation

245 Coincubation of cultured hepatocytes with 25-hydroxycholesterol suppressed squalestatin 1-mediated CY

246 n levels, whereas conversely, addition of 25-hydroxycholesterol suppressed SR-BI levels by approximat

247 undefined, that abolishes the ability of 25-hydroxycholesterol to inhibit the cleavage of both stero

248 We show that addition of cholesterol or 25-hydroxycholesterol to microsomal membranes in vitro bloc

249 After TBI, as after 24S-hydroxycholesterol treatment in vitro, SREBP-1 mRNA leve

250 r-neutrophils and gammadelta-T cells, and 27-hydroxycholesterol treatment results in a decreased numb

251 Plasma and tissue levels of 25- and 27-hydroxycholesterol, two oxysterol substrates of this enz

252 ncreased by certain oxysterols such as 22(R)-hydroxycholesterol via activation of the nuclear hormone

253 7beta-Hydroxycholesterol was also a potent inhibitor of alpha-

254 ed production of Abeta in neurons, but 24(S)-hydroxycholesterol was approximately 1000-fold more pote

255 cumulation of CYP7B1 substrates including 27-hydroxycholesterol was confirmed in serum (n = 19) and c

256 ecific 24-hydroxylase, and its product 24(S)-hydroxycholesterol was not a useful indicator in mouse p

257 In cerebrospinal fluid 27-hydroxycholesterol was reduced by 8.4% but this did not

258 27-Hydroxycholesterol was thought to be the only product fo

259 Levels of 27-hydroxycholesterol were > 4,500 times normal.

260 The Km values for corticosterone and 7alpha-hydroxycholesterol were 1.2 and 1.9 microM, respectively

261 ells, and repression of HMGR synthesis by 25-hydroxycholesterol were confirmed.

262 otent sterol repressor of HMGR synthesis (25-hydroxycholesterol), were assayed on two cell lines: Hep

263 enile hormone III), or liver X receptor (22R-hydroxycholesterol), were injected into the amniotic flu

264 cholanoate together with their precursor, 27-hydroxycholesterol, were identified in liver homogenates

265 e of molecular orientations accessible to 25-hydroxycholesterol when compared to cholesterol.

266 he central cavity of Insig-2 accommodates 25-hydroxycholesterol, whereas TM3 and TM4 engage in Scap b

267 7beta-Hydroxycholesterol, which is the most cytotoxic of the e

268 phosphatidylcholine monolayers containing 25-hydroxycholesterol, which produce both an upper and a lo

269 e most potent of regulatory oxysterols is 25-hydroxycholesterol, whose biosynthetic enzyme has not ye

270 Even though 25-hydroxycholesterol will compete for cholesterol binding

271 ar endothelial cells were treated with 22(R)-hydroxycholesterol with and without L-4F.

272 a useful method to image intracellular 20(S)-hydroxycholesterol with both high sensitivity and spatia